3.2 Chronic Coronary Disease & Antiplatelet Strategies

3.2 Chronic Coronary Disease & Antiplatelet Strategies

BCACP Exam Anchor: Ambulatory care pharmacists must excel in tailoring antianginal pharmacotherapy based on patient hemodynamics (heart rate, blood pressure, and ventricular function) while navigating complex antiplatelet regimens. Critical exam targets include P2Y12 inhibitor contraindications (e.g., prasugrel black box warnings), CYP2C19 drug interactions, DAPT duration algorithms, and the definitive transition to "double therapy" (DOAC + clopidogrel) in patients with atrial fibrillation undergoing PCI.

Chronic Coronary Disease: Pathophysiology & Management Principles

Chronic coronary disease (CCD)—formerly termed stable ischemic heart disease (SIHD)—results from an imbalance between myocardial oxygen supply and myocardial oxygen demand:

$\text{Myocardial Oxygen Demand} \propto \text{Heart Rate} \times \text{Contractility} \times \text{Left Ventricular Wall Tension (Afterload/Preload)}$

Foundational Secondary Prevention Regimen

Every patient with documented CCD must receive comprehensive secondary prevention to reduce major adverse cardiovascular events (MACE):

1. Antiplatelet Therapy: Aspirin 81 mg daily indefinitely (or clopidogrel 75 mg daily if aspirin-allergic).
2. High-Intensity Statin: Atorvastatin 80 mg daily or Rosuvastatin 20–40 mg daily to achieve $\ge 50%$ LDL-C reduction and a target $\text{LDL-C} < 55\text{ to } 70\text{ mg/dL}$. Add ezetimibe or PCSK9 inhibitors if LDL targets remain unmet.
3. Blood Pressure Control: Target $\text{BP} < 130/80\text{ mmHg}$ utilizing ACE inhibitors or ARBs, particularly if concomitant diabetes, CKD, or HFrEF is present.
4. Cardiovascular-Protective Diabetes Agents: Prioritize SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiovascular event reduction.

Stepwise Antianginal Pharmacotherapy

Antianginal medications alleviate exertional symptoms and improve exercise tolerance by reducing myocardial oxygen demand or enhancing coronary perfusion. They are sequenced according to patient-specific hemodynamics.

Sublingual Nitroglycerin Patient Counseling

All CCD patients must be prescribed sublingual nitroglycerin (SL NTG 0.4 mg) for acute angina management:

• Action Plan at Symptom Onset: Sit down immediately (prevents orthostatic syncope). Place 1 tablet under the tongue and allow it to dissolve; do not swallow or chew.
• EMS Activation Rule: If chest pain is unimproved or worsening after 5 minutes, call 911 immediately. While awaiting EMS, take a second dose 5 minutes after the first, and a third dose 5 minutes later (maximum of 3 doses in 15 minutes).
• Storage & Stability: Keep tablets in the original amber glass container with the metal cap tightly closed. Protect from heat, moisture, and light. Do not store in pill organizers or carry in pockets close to body heat. Replace opened bottles every 6 months.
• PDE-5 Inhibitor Interaction: Absolute contraindication: Do not take SL NTG within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil.

Oral Antiplatelet Agents: Comparative Pharmacology

Dual antiplatelet therapy (DAPT) combining aspirin with an oral $\text{P2Y}_{12}$ receptor antagonist is the cornerstone of post-PCI and acute coronary syndrome care.

DAPT Durations: ACS vs. Chronic Coronary Disease

The optimal duration of DAPT balances ischemic protection (preventing stent thrombosis, recurrent MI) against the risk of major bleeding.

                                Percutaneous Coronary Intervention (PCI)
                                                   │
                 ┌─────────────────────────────────┴─────────────────────────────────┐
                 ▼                                                                   ▼
     Elective PCI for Chronic CAD                                            ACS Presentation (STEMI/NSTEMI)
                 │                                                                   │
     ┌───────────┴───────────┐                                           ┌───────────┴───────────┐
     ▼                       ▼                                           ▼                       ▼
Standard Bleeding Risk    High Bleeding Risk (HBR)               Standard Bleeding Risk    High Bleeding Risk (HBR)
(PRECISE-DAPT <25)        (PRECISE-DAPT ≥25 / ARC-HBR)           (PRECISE-DAPT <25)        (PRECISE-DAPT ≥25 / ARC-HBR)
     │                       │                                           │                       │
  6 Months DAPT           1-3 Months DAPT                             12 Months DAPT          1-6 Months DAPT
(Aspirin + Clopidogrel)   (Short DAPT → Monotherapy)             (Aspirin + Ticagrelor/    (Short DAPT → P2Y12i Monotherapy
     │                                                                 Prasugrel)                 or Aspirin)
     ▼                                                                   │
Lifelong Single Antiplatelet                                             ▼
  (Aspirin 81 mg daily)                                         Lifelong Single Antiplatelet
                                                                   (Aspirin 81 mg daily)

• Standard ACS Post-PCI: 12 months of DAPT with aspirin 81 mg + potent $\text{P2Y}_{12}$ inhibitor (ticagrelor or prasugrel preferred over clopidogrel based on PLATO and TRITON-TIMI 38 trials).
• Elective Stenting for Chronic CAD: 6 months of DAPT with aspirin 81 mg + clopidogrel 75 mg daily.
• High Bleeding Risk (HBR) Customization: In patients with high bleeding risk (e.g., PRECISE-DAPT score $\ge 25$, ARC-HBR criteria met, severe thrombocytopenia, recent bleeding):
  • ACS: Shorten DAPT to 1 to 6 months, followed by $\text{P2Y}_{12}$ inhibitor monotherapy (ticagrelor or clopidogrel) or aspirin.
  • Chronic CAD: Shorten DAPT to 1 to 3 months, followed by single antiplatelet monotherapy.

Atrial Fibrillation + PCI: Double vs. Triple Therapy

When a patient with an indication for oral anticoagulation (e.g., atrial fibrillation with $\text{CHA}_2\text{DS}_2\text{-VASc} \ge 2$ in men or $\ge 3$ in women) undergoes PCI, combining full-dose anticoagulation with DAPT ("Triple Therapy") produces an unacceptable 3- to 4-fold increase in major bleeding.

Modern Consensus: Double Therapy as the Default Strategy

Landmark clinical trials (PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI) demonstrated that omitting aspirin upon hospital discharge dramatically reduces major bleeding by 40% to 50% with no statistically significant increase in stent thrombosis or ischemic stroke.

• Default Regimen ("Double Therapy"): DOAC (at standard stroke-prevention dose) + Clopidogrel 75 mg daily.
• Aspirin Duration: Aspirin 81 mg is administered during the acute PCI procedure and discontinued at hospital discharge (or continued for up to 1 to 4 weeks only in rare cases with extreme anatomical thrombotic risk and low bleeding risk).
• $\text{P2Y}_{12}$ Inhibitor Selection: Clopidogrel 75 mg daily is the mandatory $\text{P2Y}_{12}$ inhibitor of choice. Prasugrel and ticagrelor are strictly avoided in double/triple therapy regimens due to unacceptably high rates of major hemorrhage.
• Duration of Double Therapy: Clopidogrel is continued for 6 to 12 months post-PCI. After 6 to 12 months, the antiplatelet agent is permanently discontinued, and the patient continues lifelong DOAC monotherapy.